Want to see TSE:EPRX full AI Analyst Report?
Top Page
Eupraxia Pharmaceuticals
(TSX:EPRX)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$9.00
▲(9.49% Upside)
Action:Reiterated
Date:08/17/26
The score is primarily constrained by weak financial performance typical of a pre-revenue biotech (widening losses and cash burn), partially offset by a low-debt, equity-supported balance sheet. Technical indicators are modestly positive in the near term but still below longer-term trend levels, and valuation is limited by negative earnings and no dividend yield.
Positive Factors
Proprietary drug-delivery platform
DiffuSphere provides a differentiated delivery approach intended to sustain local treatment while reducing systemic exposure. If validated clinically, the platform could support multiple inflammatory indications and create longer-term product or licensing opportunities.
Negative Factors
Pre-revenue business model
With no commercialized product revenue, Eupraxia lacks an operating revenue base to fund research, development, and corporate costs. Financial performance therefore depends on successful approvals and commercialization, leaving the business exposed to clinical and regulatory setbacks.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary drug-delivery platform
DiffuSphere provides a differentiated delivery approach intended to sustain local treatment while reducing systemic exposure. If validated clinically, the platform could support multiple inflammatory indications and create longer-term product or licensing opportunities.
Read all positive factors
Eupraxia Pharmaceuticals (EPRX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$646.08M
Dividend YieldN/A
Average Volume (3M)74.24K
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue GrowthN/A
EPS Growth-15.34%
CountryCA
Employees49
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.02
Shares Outstanding65,906,630
10 Day Avg. Volume63,163
30 Day Avg. Volume74,239
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)5.04
Price to Sales (P/S)0.00
P/FCF Ratio-13.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$23.57Price Target Upside186.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.84
Revenue Forecast (FY)N/A
Eupraxia Pharmaceuticals Business Overview & Revenue Model
Company Description
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, tar...
How the Company Makes Money
As a clinical-stage company, Eupraxia Pharmaceuticals does not have publicly known, material recurring revenue from commercialized products; its current operations are primarily funded through financing activities rather than product sales. The co...
Eupraxia Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -358.86K | -241.88K | -163.47K | -158.05K | -193.27K | -111.53K |
| EBITDA | -55.76M | -38.86M | -23.43M | -28.16M | -22.14M | -21.96M |
| Net Income | -49.89M | -39.25M | -24.28M | -28.15M | -23.26M | -22.99M |
Balance Sheet | ||||||
| Total Assets | 139.68M | 85.99M | 34.94M | 20.12M | 25.88M | 31.22M |
| Cash, Cash Equivalents and Short-Term Investments | 133.44M | 80.42M | 33.10M | 19.34M | 24.74M | 29.90M |
| Total Debt | 1.84M | 154.08K | 71.86K | 10.45M | 10.55M | 9.49M |
| Total Liabilities | 10.22M | 5.69M | 3.10M | 19.23M | 14.51M | 11.67M |
| Stockholders Equity | 131.06M | 81.89M | 33.40M | 2.21M | 12.86M | 20.39M |
Cash Flow | ||||||
| Free Cash Flow | -36.57M | -29.65M | -30.10M | -21.09M | -19.08M | -15.07M |
| Operating Cash Flow | -35.84M | -29.05M | -29.99M | -21.02M | -18.78M | -14.64M |
| Investing Cash Flow | -79.50M | -599.26K | -75.16K | -73.20K | 8.70M | -14.45M |
| Financing Cash Flow | 129.47M | 77.39M | 45.78M | 21.35M | 13.52M | 49.92M |
Eupraxia Pharmaceuticals Technical Analysis
Neutral
8.22
Price Trends
9.10
Positive
9.43
Negative
9.83
Negative
Market Momentum
0.11
Negative
51.65
Neutral
59.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EPRX, the sentiment is Neutral. The current price of 8.22 is below the 20-day moving average (MA) of 9.11, below the 50-day MA of 9.10, and below the 200-day MA of 9.83, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 51.65 is Neutral, neither overbought nor oversold. The STOCH value of 59.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:EPRX.
Eupraxia Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
TSE:EPRX
Eupraxia Pharmaceuticals
9.32
2.12
29.44%
TSE:DRUG
Bright Minds Biosciences
109.41
50.85
86.83%
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
TSE:MBIO
Mindbio Therapeutics Corp.
0.18
-3.82
-95.50%
Eupraxia Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Eupraxia Deepens Investment in EP-104GI as New Data Strengthen EoE Prospects
Positive
Aug 11, 2026
Eupraxia Pharmaceuticals reported a wider second-quarter net loss of $14.5 million, up from $8.7 million a year earlier, as it doubled the size of its RESOLVE Part 2 trial and expanded its organizational footprint to Vancouver and Seattle. Despite...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.